Source comparison
BPC-157 for Joint Support: Protocol Comparison
Daily Dose 200–250mcg once daily 400–500mcg once daily (or split into 250mcg twice daily) Higher doses show no additional benefit in rat models above 10mcg/kg; 250mcg is the evidence-backed sweet spot for a 70kg subject Injection Proximity Within 2–3 inches of
This comparison does not assign a generated winner or score.
- Daily Dose
- 200–250mcg once daily
- 400–500mcg once daily (or split into 250mcg twice daily)
- Higher doses show no additional benefit in rat models above 10mcg/kg; 250mcg is the evidence-backed sweet spot for a 70kg subject
- Injection Proximity
- Within 2–3 inches of injury site
- Directly into peritendinous tissue or muscle belly adjacent to the tendon
- Proximity matters. Systemic injection (abdomen, thigh) underperforms local depot effects
- Cycle Length
- 4 weeks
- 6 weeks
- Align with collagen proliferation phase (days 7–42 post-injury); extending beyond 6 weeks adds minimal value
- Frequency
- Once daily, morning
- Twice daily (AM/PM split dose)
- Once-daily dosing is sufficient given local depot effects; splitting doesn't improve outcomes in published research
- Storage Post-Reconstitution
- Refrigerated 2–8°C, discard after 28 days
- Bacteriostatic water permits 28-day multi-dose use; freezing reconstituted peptides causes irreversible aggregation